Moreover, SGLT2 inhibitors have been reported to be protective for a variety of other traits, such as heart failure, CKD, cardiovascular disease, weight management, and BP control.23, , , –27 With this in mind, we consolidated the statistically significant and known P/LP variants together and conducted a PheWAS using curated PheCodes.16 Although not statistically significant, given the multiple comparison testing, variants were associated with an increased risk of glucosuria (P = 5.09E-4; OR, 2.80; 95% CI, 1.57 to 4.99). This evidence concerns the gene SLC5A2 and cardiovascular disorder.